Synthesis and biological evaluation of aryl phosphoramidate prodrugs of fosfoxacin and its derivatives

Add time:07/24/2019    Source:sciencedirect.com

Aryl phosphoramidate prodrugs of fosfoxacin derivatives 15a-b and 8a-b were synthesized and investigated for their ability to target bacteria. No growth inhibition was observed neither for Mycobacterium smegmatis nor for Escherichia coli on solid medium, demonstrating the absence of release of the active compounds in the bacterial cells. Investigation of the stability of the prodrugs and their multienzymatic cleavage in abiotic and biotic conditions showed that the use of aryl phosphoramidate prodrug approach to deliver non-nucleotides compounds is not obvious and might not be appropriate for an antimicrobial drug.

We also recommend Trading Suppliers and Manufacturers of DIETHYL PHOSPHORAMIDATE (cas 1068-21-9). Pls Click Website Link as below: cas 1068-21-9 suppliers

Prev:Kinetics of tris (1-chloro-2-propyl) phosphate (TCIPP) metabolism in human liver microsomes and serum
Next:Parametric studies of DIETHYL PHOSPHORAMIDATE (cas 1068-21-9) photocatalytic decomposition over TiO2)